Effect of propranolol and IFN-β on the induction of MHC class II expression and cytokine production by IFN-γ in THP-1 human monocytic cells

Immunopharmacology and Immunotoxicology

Volumn 20, Issue 1, 1998, Pages 39-61

  Li, Qingdi ^a   Milo, Ron ^b   Panitch, Hillel ^d   Bever Jr , Christopher T ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c UMH   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROPRANOLOL;

ANTIGEN EXPRESSION; ARTICLE; DRUG EFFECT; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; PRIORITY JOURNAL;

EID: 0031953312     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979809034808     Document Type: Article

References (95)

1. McFarlin DE and McFarland HF. Multiple sclerosis. N. Engl. J. Med., 307:1183-1188, 1246-1251, 1982.
2. Raine C. The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesions. Ann. Neurol., 36(suppl.):S61-72, 1994.
3. Navikas V and Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res., 45:322-333, 1996.
4. Cannella BC and Raine CS. The adhesion molecules and cytokine profile of multiple sclerosis lesion. Ann. Neurol., 37:424-435, 1995.
5. Tsukada N, et al. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurosci., 102:230-234, 1991.
6. Selmaj K, Raine CS, Cannella B and Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest., 87:949-954, 1991.
7. Selmaj K and Raine C. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol., 23:339-346, 1988.
8. Selmaj K, Farooq M, Norton W, et al. Proliferation of astrocytes in vitro in response to cytokines: A primary role for tumor necrosis factor. J. Immunol., 144:129-135, 1990.
9. Adams DO and Hamilton TA. The cell biology of macrophage activation. Ann. Rev. Immunol., 2:283-318, 1984.
10. Adams DO and Hamilton TA. Molecular transductional mechanisms by which IFN-γ and other signals regulate macrophage development. Immunol. Rev., 97:5, 1987.
11. Adams D and Hamilton T. Molecular basis of macrophage activation: diversity and its origins. In: The Macrophage: The Natural Immune System, edited by Lewis L and McGee J, p.75-105, IRL Press, Oxford, 1992.
12. Sen GC and Lengyel P. The interferon system. A bird's eye view of its biochemistry. J. Biol. Chem., 267:5017-5020, 1992.
13. Vassalli P. The pathophysiology of tumor necrosis factor. Annu. Rev. Immunol., 10:411-452, 1992.
14. Cannella B and Raine CS. Cytokines up-regulate Ia expression in organotypic cultures of CNS tissue. J. Neuroimmunol., 24:239-248, 1989.
15. Rieckmann P, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol., 37:82-88, 1995.
16. Sharief M and Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med., 325:467-472, 1991.
17. Koide Y, Ina Y and Nezu N. Calcium influx and the calcium-calmodulin complex are involved in interferon-γ-induced expression of HLA class II molecules on HL-60 cells. Proc. Natl. Acad. Sci. USA, 85:3120-3124, 1988.
18. Fan X-D, Goldberg M and Bloom BR. Interferon-γ-induced transcriptional activation is mediated by protein kinase C. Proc. Natl. Acad. Sci. USA, 85:5122-5125, 1988.
19. Besta PV, et al. A β-adrenergic agonist modulates DRa gene transcription via enhanced cAMP levels in a glioblastoma multiforme line. J. Immunol., 142:2895-2901, 1989.
20. Celada A and Maki RA. IFN-γ induces the expression of the genes for MHC class II I-Ab and tumor necrosis factor through a protein kinase C-independent pathway. J. Immunol., 146:114-120, 1991.
21. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature, 308:693-698, 1984.
22. Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science, 225:1365-1370, 1984.
23. Majerus PW, et al. Recent insights in phosphatidylinositol signaling, cell, 63:459, 1990.
24. Exton JH. Signaling through phosphatidylcholine breakdown. J. Biol. Chem., 265:1-4, 1990.
25. Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim. Biophys. Acta, 1212:26-42, 1994.
26. Thompson NT, et al. Receptor-coupled phospholipase D and its inhibition. Trands Pharmacol. Sci., 12:404-408, 1991.
27. Noronha A, et al. Interferon-β decreases T cell activation and interferon-γ production in multiple sclerosis. J. Neuroimmunol., 46:145-153, 1993.
28. Rudick RA, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology, 43:2080-2087, 1993.
29. Khabar KSA. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J. Leukoc. Biol., 52:165-172, 1992.
30. Barna BP, et al. Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J. Neuroimmunol., 23:45-53, 1989.
31. Ling PD, et al. Antagonistic effect of interferon-β on the interferon-γ-induced expression of Ia antigen in murine macrophages. J. Immunol, 135:1857-1863, 1985.
32. Inaba K, et al. Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigen. J. Exp. Med., 163:1030-1035, 1986.
33. Auwerx J. The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation. Experimentia, 47:22-30, 1991.
34. Hidaka H, Inagaki M, Kawamoto S and Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry, 23:5036-5041, 1984.
35. ++ dependent protein kinase. Biochem. Biophys. Res. Commun., 135:397-402, 1986.
36. 3H]-staurosporine on various protein kinases. Biochem. Biophys. Res. Commun., 171:189-195, 1990.
37. Gschwendt W, Horn F, Kittstein W, Fuerstenberg G, Besemfelder E and Marks F. Calcium and phospholipid-dependent protein kinase activity in mouse epidermis cytosol. Stimulation by complete and incomplete tumor promoters and inhibition by various compounds. Biochem. Biophys. Res. Commun., 124:63-68, 1984.
38. Cheng K, Chan WW-S, Butler B, Barreto AJ and Smith RG. Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp-D-Phe-Lys-NH2-induced growth hormone release from rat primary pituitary cells. Endocrinology, 129:3337-3342, 1991.
39. Toullec D, Pianetti P, Coste H, Bellevergue P, et al. The bisindolylmaleimide GF 1092203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266:15771-15781, 1991.
40. Davis PD, Elliott LH, Harris W, Hill CH, et al. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J. Med. Chem., 35:994-1001, 1992.
41. Veis N, Rosen A and Aderem A. Microtubule-active agents mimic lipopolysaccharides in priming macrophages for enhanced arachidonic acid metabolism. J. Inflamm., 46:106-113, 1996.
42. 2 by diacylglycerol. Biochem. J., 248:779-783, 1987.
43. Murakami K and Routtenberg A. Direct activation of purified protein kinase C by unsaturated fatty acids (oleate and arachidonate) in the absence of phospholipid and calcium. FEBS Lett., 192:189, 1985.
44. Fan X, et al. Arachidonic acid and related methyl ester mediate protein kinase C activation in intact platelets through the arachidonate metabolism pathways. Biochem. Biophys. Res. Commun., 169:933, 1990.
45. Dore-Duffy P, Donaldson J, Koff T, et al. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology, 36:2593-2597, 1986.
46. Dore-Duffy P, Donovan C and Todd RFI. Expression of monocyte activation antigen Mo3 on the surface of peripheral blood monocytes from patients with multiple sclerosis. Neurology, 42:1609-1614, 1992.
47. Merrill J, Strom S, Ellison G, et al. In vitro study of mediators of inflammation in multiple sclerosis. J. Clin. Immunol., 9:84-96, 1989.
48. Prineas J and Graham J. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin dreakdown. Ann. Neurol., 10:149-158., 1981.
49. Prineas JW and Wright RG. Macrophges, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest, 38:409-418, 1978.
50. Black DM, Catteral JR and Remington JS. In vivo and in vitro activation of alveolar macrophages by recombinant interferon-γ. J Immunol, 138:491-495, 1987.
51. Panitch HS, Hirsch RL, Schindler J and Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet, 1:893-895, 1987.
52. Traugott U, Lebon P and Raine CS. Multiple sclerosis: Possible role of interferon gamma for reactivation of the disease process. J Neuropath Exp Neurol, 46:366-372, 1987.
53. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor in MS. Acta Neurologica Scand, 78:318-323, 1988.
54. Traugott U and Lebon P. Multiple sclerosis: Involvement of interferons in lesion pathogenesis. Ann. Neurol., 24:243-251, 1988.
55. Li Q, Milo R, Bever CT, Swoveland P and Panitch H. Protein kinase C regulates HLA class II molecule expressions and TNF-α production in THP-1 cells. FASEB J., 8:A506, 1994.
56. Li Q, Bever CT. Gamma interferon induced increases in intracellular cathepsin B activity in PMA primed THP-1 cells are blocked by inhibitors of protein kinase C. Immunopharmacol. Immunotoxicol., 18:375-396., 1996.
57. Robbins D, Shirazi Y, Drysdale B, et al. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J. Immunol., 139:2593-2597, 1987.
58. Durum S and Oppenheim J. Macrophage-derived mediators: interleukin-1, tumor necrosis factor, interleukin-6, and related cytokines. In: Fundamental immunology, edited by Paul W, 639-661, Raven Press, New York, 1989.
59. Old L. Polypeptide mediator network. Nature, 326:330-331, 1987.
60. + current expression in cultured oligodendrocytes. J. Membrane Biol., 124:127-137, 1991.
61. Hofman F, Hinton D, Johnson K, et al. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med., 170:607-612, 1989.
62. Giulian D and Lachman L. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science, 228:497-499, 1985.
63. Interferon-β Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology, 43:662-667, 1993.
64. Cieri M and Bever CT. Gamma interferon induced increases in cathepsin B activity are blocked by alpha and beta interferons (Type I interferon). FASEB J., 4:A339, 1990.
65. Whitaker JN, Heineman MA and Uzman BG. The renal degradation of MBP peptide 43-88 by two enzymes in different subcellular fractions. Biochem J, 201:543-553, 1982.
66. Berlet HH and Ilzenhofer H. Elucidation of cathepsin B-like activity associated with extracts of human myelin basic protein. FEBS Lett., 179:299-302, 1985.
67. Yanagisawa K, Sato S, Miyatake T, Kominami E and Katsunuma N. Degradation of myelin protein by cathepsin B and inhibition by E-64 analogue. Neurochem. Res., 9:691-694, 1984.
68. Garotta G, et al. Functional antagonism between type I and Type II interferons on human macrophages. Biochem. Biophys. Res. Commun., 140:948-954, 1986.
69. Alan R, et al. Interferon alpha/beta selectively antagonizes down-regulation of mannosyl-fucosyl receptors on activated macrophages by interferon gamma. Biochem. Biophys. Res. Commun., 136:737-744, 1986.
70. Unanue E, Beller D, Lu C, et al. Antigen presentation: comments on its regulation and mechanism. J. Immunol., 132:1-4, 1984.
71. Chou Y, Vainiene M, Whitham R, et al. Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules. J. Neurosci. Res., 23:207-216, 1989.
72. Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from mutiple sclerosis patients and healthy individuals. J. Immunol., 145:540-548, 1990.
73. Ota K, Matsui M, Milford E, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature, 346:183-187, 1990.
74. Pette M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin-basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. USA, 87:7968-7972, 1990.
75. Pitzurra L, Blasi E, Puliti M and Bistoni F. Toxic effects of tetanus toxin on GG2EE macrophages: prevention of gamma interferon-mediated upregulation of lysozyme-specific mRNA levels. Infect. Immun., 61:3605-3610, 1993.
76. Brown D, Faris M, Hilburger M and Zwilling BS. The induction of persistence of I-A expression by macrophages from Bcgr mice occurs via a protein kinase C-dependent pathway. J. Immunol., 152:1323-1331, 1994.
77. Sands WA, Clark JS and Liew FY. The role of a phosphatidylcholine-specific phospholipase C in the production of diacylglycerol for nitric oxide synthesis in macrophages activated by IFN-γ and LPS. Biochem. Biophys. Res. Commun., 199:461-466, 1994.
78. Politis AD, Sivo J and Vogel SN. Multiple pathways of interferon-induced gene expression in murine macrophages. J. Leukoc. Biol., 53:583-590, 1993.
79. Jun CD, Choi BM, Kim HM and Chung HT. Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J. Immunol., 154:6541-6547, 1995.
80. Suk K, Somers SD and Erickson KL. Regulation of murine macrophage function by IL-4: IL-4 and IFN-γ differentially regulate macrophage tumoricidal activation. Immunology, 80:617-624, 1993.
81. Sands WA, Bulut V, Severn A, Xu D and Liew FY. Inhibition of nitric oxide synthesis by interleukin-4 may involve inhibiting the activation of protein kinase C epsilon. Eur. J. Immunol., 24:2345-2350, 1994.
82. Weiel JE, Adams DO and Hamilton TA. Biochemical models of gamma-interferon action: altered expression of transferrin receptors on murine peritoneal macrophages after treatment in vitro with PMA or A23187. J. Immunol., 134:293-298, 1985.
83. Celada A and Schreiber RD. Role of protein kinase C and intracellular calcium mobilization in the induction of macrophage tumoricidal activity by interferon-γ. J. Immunol., 137:2373-2379, 1986.
84. Somers SC, Weiel JE, Hamilton TA and Adams DO. Phorbol esters and calcium ionophore can prime murine peritoneal macrophages for tumor cell destruction. J. Immunol., 136:4199-4205, 1986.
85. Gumina RJ, Freire-Moar J, DeYoung L, Webb D and Devens BH. Transduction of the IFN-γ signal for HLA-DR expression in the promonocytic line THP-1 involves a late acting PKC activity. Cell. Immunol., 138:265-279, 1991.
86. + entry. J. Biol. Chem., 266:18119-18126, 1991.
87. Politis AD and Vogel SN. Pharmacologic evidence for the requirement of protein kinase C in IFN-induced macrophage Fcγ receptor and Ia antigen expression. J. Immunol., 145:3788-3795, 1990.
88. Nezu N, et al. Regulation of HLA class II molecule expressions by IFN-γ: The signal transduction mechanism in glioblastoma cell lines. J. Immunol., 145:3126-3135, 1990.
89. Mattila P, Hayry P and Renkonen R. Protein kinase C is crucial in signal transduction during gamma-interferon induction in endothelial cells. FEBS Lett., 250:362-366, 1989.
90. Yoshida A, Koide Y, Uchijima M and Yoshida TO. IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem. Biophys. Res. Commun., 198:857-861, 1994.
91. Muller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK complements defects in interferon alpha/beta and gamma signal transduction. Nature, 366:129-135, 1993.
92. Watling D, Guschin D, Muller M, et al. Complementation by the protein tyrosine kinase Jak 2 of a mutant cell line defective in the interferon-γ signal transduction pathway. Nature, 366:166-170, 1993.
93. Igarashi K, Garotta G, Ozmen L, et al. Interferon-γ induces tyrosine phosphorylation of the interferon-γ receptor and the regulated association of the protein tyrosine kinases, Jak1 and Jak2, with its receptor. J. Biol. Chem., 269:14333, 1994.
94. Darnell JE, Kerr IM and Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264:1415-1421, 1994.
95. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43:851-856, 1989.